Annabel Samimy
Stock Analyst at Stifel
(4.54)
# 283
Out of 5,182 analysts
57
Total ratings
51.85%
Success rate
41.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCS Oculis Holding AG | Maintains: Buy | $40 → $50 | $27.11 | +84.43% | 3 | Mar 5, 2026 | |
| EOLS Evolus | Maintains: Buy | $20 → $17 | $5.22 | +225.67% | 2 | Jan 13, 2026 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $15 → $18 | $14.27 | +26.14% | 1 | Dec 19, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Hold | $50 → $55 | $49.33 | +11.49% | 8 | Dec 19, 2025 | |
| RGNX REGENXBIO | Maintains: Buy | $40 → $45 | $8.62 | +422.04% | 3 | Dec 19, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $45 → $52 | $26.99 | +92.66% | 2 | Dec 19, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $45 → $50 | $31.97 | +56.40% | 2 | Dec 19, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $55 → $48 | $40.95 | +17.22% | 4 | Dec 19, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $220 → $230 | $241.79 | -4.88% | 2 | Dec 10, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $90 | $45.33 | +98.54% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $145 | $128.64 | +12.72% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.80 | +542.86% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $5.13 | +231.38% | 4 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $8.20 | +119.51% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $11.59 | +107.08% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $32.99 | +142.53% | 6 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $230 | $201.22 | +14.30% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $0.89 | +2,596.93% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $2.07 | +36,131.88% | 3 | Apr 16, 2020 |
Oculis Holding AG
Mar 5, 2026
Maintains: Buy
Price Target: $40 → $50
Current: $27.11
Upside: +84.43%
Evolus
Jan 13, 2026
Maintains: Buy
Price Target: $20 → $17
Current: $5.22
Upside: +225.67%
Trevi Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $15 → $18
Current: $14.27
Upside: +26.14%
Supernus Pharmaceuticals
Dec 19, 2025
Maintains: Hold
Price Target: $50 → $55
Current: $49.33
Upside: +11.49%
REGENXBIO
Dec 19, 2025
Maintains: Buy
Price Target: $40 → $45
Current: $8.62
Upside: +422.04%
Mineralys Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $52
Current: $26.99
Upside: +92.66%
MBX Biosciences
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $31.97
Upside: +56.40%
Apellis Pharmaceuticals
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $40.95
Upside: +17.22%
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $241.79
Upside: -4.88%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $50 → $90
Current: $45.33
Upside: +98.54%
Nov 24, 2025
Maintains: Buy
Price Target: $87 → $145
Current: $128.64
Upside: +12.72%
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $2.80
Upside: +542.86%
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $5.13
Upside: +231.38%
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $8.20
Upside: +119.51%
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $11.59
Upside: +107.08%
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $32.99
Upside: +142.53%
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $201.22
Upside: +14.30%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $0.89
Upside: +2,596.93%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $2.07
Upside: +36,131.88%